Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
Completed
GE Healthcare
Phase 3
2005-08-02
The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent
in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
Completed
GE Healthcare
Phase 3
2005-07-01
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to
predict cardiac outcomes in subjects with heart failure and in comparison to subjects without
cardiovascular disease.
Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
Completed
GE Healthcare
Phase 3
2005-07-01
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to
predict cardiac outcome in subjects with heart failure and in comparison to subjects without
cardiovascular disease.
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Completed
Molecular Insight Pharmaceuticals, Inc.
Phase 1
2006-06-01
The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131
that has radioactivity, to measure how long it takes for the drug to be absorbed and passed
out of the body, and to measure how much radioactivity is absorbed into different tissues of
the body.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
